The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1´) inhibitors and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.L'invention concerne des compositions pharmaceutiques comprenant de la caséine kinase 1 delta (CK1δ) et l'utilisation desdits inhibiteurs dans le traitement de troubles neurodégénératifs tels que la maladie d'Alzheimer.